Introduction: Cough is frequent symptom in sarcoidosis and there are no specifi c tools for measurement of its severity in Serbia. Aim: The goal of this study was to translate and validate the Serbian version of the Leicester Cough Questionnaire (LCQ) in a population of sarcoidosis patients. Methods: After the LCQ forward-backward translation process, in the cross-sectional study in 275 (180 female) sarcoidosis patients Serbian version of the LCQ was administered together with other standardized instruments for measurement of Patient Reported Outcomes (PROs) -symptoms of dyspnea (assessed by MRC and Borg scales) and fatigue (measured by Fatigue Assessment Scale and List of Daily Activities), and patients' health status (assessed by generic tool -15D). Pulmonary function tests (spirometry and diff using capacity for carbon monoxide) were also measured. Results: Serbian LCQ version showed excellent internal consistency (Cronbach's alpha of its diff erent scores ranged between 0.901 for physical domain and 0.951 for the total score). Concurent validity assessed by correlations of all LCQ scores with other PROs and pulmonary function tests was very good, since all these correlations were statistically signifi cant. Conclusions: Our results confi rmed that the Serbian version of LCQ is a valid instrument to monitor the infl uence of chronic cough on quality of life in sarcoidosis patients.
INTRODUCTION
Sarcoidosis is a chronic multisystem granulomatous disease of unknown origin that is most commonly present in the lungs but may also involve any other organ [1] .
Patients with pulmonary sarcoidosis may have symptoms related directly to the chest such as dyspnea on exertion, chest pain, chest discomfort, cough, and wheeze. Patients may also develop symptoms related to extrapulmonary organ involvement. In addition, sarcoidosis may cause constitutional symptoms such as fatigue, fever, anorexia, weight loss, generalized weakness, and pain that are not attributable to involvement of any specifi c organ [2, 3] .
Nowadays design of most of the international clinical drug trials includes Patient-Reported Outcomes (PROs) as study endpoints, and their changes during treatment period represent either secondary and exploratory (in phases II or IIIa) or even primary (in phases IIIb and IV) study objectives. Food and Drug Administration (FDA) defi nes PROs as measurement of any aspect of a patient's health status that comes directly from the patient, without interpretation of the patient's responses by a physician or anyone else [4] . PROs encompass symptoms and signs of disease, treatment satisfaction and quality of life (QoL) of patients. Th is is increasingly observed as the regulatory authorities' requirement due to several limitations of the objective disease outcomes, like pulmonary function tests or radiographic fi ndings. Moreover, numerous studies showed that correlations between PROs as subjective outcomes and objective outcomes are rather mild or moderate or even do not exist at all [5] .
Th e assessment of all endpoints should be possible in all subjects in a consistent and reproducible manner, using the same techniques applicable to all subjects in the study. Th us, questionnaires have been developed and validated in order to assess PROs in a standardized way.
Recently, more attention has been paid to the cough in patients with sarcoidosis and we now have a validated tool -Leicester Cough Questionnaire (LCQ) for measuring this important symptom [6] . Currently only a few studies used LCQ for assessing cough in sarcoidosis patients [7] [8] [9] .
LCQ is a 19-item validated specifi c QoL measure of cough over the period of privious two weeks [6] . Its scores can be calculated in 3 domains covering physical (8 items), psychological (7 items), and social (4 items) aspect of chronic cough, in addition to the total score. It evaluates the impact of cough on patients' quality of life. It takes 5 to 10 minutes to complete. Scores are calculated by domain (range from 1 to 7) and then added to obtain the total score (range from 3 to 21), with higher scores indicating a better QoL. Th e LCQ has been translated into several languages including Dutch, Korean, Lithuanian, Mandarin, Polish, Portuguese, German and Spanish, and validated in corresponding cohorts [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . It has been also validated for diff erent diseases, like chronic cough itself, cystic fi brosis including aff ected children, bronchiectasis, COPD [17, [20] [21] [22] , and recently for sarcoidosis [8] . A validated Serbian version does not exist, so our aim was to translate and validate Serbian version of the LCQ in sarcoidosis patients in order to provide an instrument for future multinational studies on chronic cough in sarcoidosis patients in particular.
METHODS
Th e original English version of the LCQ was translated into Serbian language in a forwardbackward approach. Th ree authors (BSG, VMV, MHV) independently translated the LCQ nad mutually agreed about the fi nal working Serbian version. Aft er that the professional translator experienced and familiar with medical terminology performed back-translation of the agreed Serbian version. Aft er comparing back-translated LCQ version with the original one, the authors agreed that there was no need for further corrections of the Serbian version. So, this Serbian version of the LCQ was initially administered among ten sarcoidosis patients at the Clinic for Pulmonology, Clinical Center of Serbia in Belgrade, Serbia, in order to assess their understanding of each particular question. All of them understood questions from the questionnaire very well and had no additional questions. Th erefore, the implemented version of the LCQ did not need any modifi cations and we accepted it as the fi nal Serbian version.
Most patients recruited in this cross- Th is study was approved by the institution's ethics committee and all patients consented to participation.
Validity of the Serbian version of the LCQ was examined by the assessment of internal consistency (calculating the Cronbach's Alpha coeffi cient) and concurrent validity (correlating the LCQ scores with other standardized instruments for measurement of symptoms of dyspnea and fatigue, health status and pulmonary function parameters in sarcoidosis patients).
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Following PROs were administered: 1) Dyspnea instruments: Modifi ed Medical Research Council (MRC) Dyspnea Scale [23] and Borg dyspnea category-ratio-10 scale (CR-10) [24] , 2) Fatigue questionnaires: Fatigue Assessment Scale (FAS) [25] and Daily Activity List (DAL) [26] , and 3) QoL scales: LCQ [6] and General health status questionnaire 15D [27] .
Modifi ed Medical Research Council (MRC) Dyspnea Scale classifi es subjects into one of fi ve categories according to their degree of dyspnea when performing certain activities [23] . Scores range from the 0 to 4, with the higher scores indicating more severe dyspnea. We previously used it in patients with sarcoidosis [28, 29] .
Borg dyspnea category-ratio-10 scale (CR-10) [24] is an 11-point scale on which dyspnea is graded from 0 (nothing at all) to 10 (maximum). It is widely used in clinical trials in diff erent respiratory and cardiovascular diseases.
Fatigue was assessed by the standardized Fatigue Assessment Scale (FAS) [25] . Th e FAS is a 10-item self-report fatigue questionnaire. Th e response scale is a 5-point Likert scale (1 never to 5 always). Total scores on the FAS can range from 10 to 50, with high scores indicating more fatigue. FAS total score < 22 indicates no fatigue. Th e psychometric properties (reliability and validity) of the FAS are good, and it was also shown in sarcoidosis patients [30, 31] . Th e Serbian version proved to be valid in rheumatoid arthritis [32] and sarcoidosis [33] . Th e degree of limitation in daily life activities was evaluated with the Daily Activity List (DAL), a scale that was originally designed by Stewart and coworkers [26] . It has 11 items that are related to the usual activities that persons with good health can perform without particular eff ort. Th e number of positive responses comprises the DAL score and indicates the degree of impairment. Th e scale has been used in several studies in patients with chronic pulmonary diseases [34, 35, 28] .
We used the standardized questionnaire for the measuring of health status: a generic measure -Th e fi ft een-dimensional measure scale of health-related quality of life (15D) [27] . 15D is a multiatributive instrument for measurement of health-related quality of life that was initially developed and validated in a large Finnish population. It consists of 15 different and mutually exclusive health dimensions, each represented by one item. Th e total questionnaire score ranges between 0 and 1, where 1 signifi es the highest level of health status. 15D was used in diff erent diseases in many diff erent countries. Th e Serbian version of 15D was previously used in patients with sarcoidosis where it demonstrated good psychometric measurement properties [28, 36] .
On the same day subjects completed the questionnaires and performed pulmonary function tests -spirometry and the transfer factor of the lung for carbon monoxide (DLCO). Spirometry parameters included pre-bronchodilator forced expiratory vital capacity (FVC), forced expiratory volume in one second (FEV 1 ), FEV 1 /FVC, peak expiratory fl ow (PEF) and it was measured with a pneumotachograph (Masterlab, Jaeger, Wurzburg, Germany). DLCO was measured using the single-breath method (Masterlab, Jaeger, Wurzburg, Germany). Th e European Respiratory Society criteria for lung function impairments was used [37] .
A probability value of p < 0.05 was considered to be statistically signifi cant, and p < 0.01 highly statistically signifi cant. Statistical analysis was performed using the standard computer statistical package ("SPSS Version 18.0 for Windows", 2011).
RESULTS
Th e descriptive statistics for PRO scores and pulmonary function tests for all 275 subjects are presented in Table 1 . Th e total time required to complete the LCQ, dyspnea and fatigue scales and 15D questionnaire ranged from 30 to 40 min.
Indicators for internal consistency are presented in Table 2 . Cronbach's alpha of diff erent LCQ scores ranged between 0.901 for physical domain and 0.951 for the total score.
Regarding the concurrent validity, we observed strong correlations (all in the expected directions) of all LCQ scores with all examined dyspnea and fatigue scores (Table 3) . It was also the case with 15D scores. All correlations, as assessed by the Pearson's coeffi cient of linear correlaton, were highly statistically signifi cant (p<0.001 for all correlations). Th e highest correlation coeffi cients with all PROs' scores were noticed for the LCQ Physical domain score. Th ey were particularly high with DAL scale and 15D (Pearson coeffi cient 0.636 and 0.632, respectively).
As pulmonary sarcoidosis is thought to be an interstitial lung disease, the traditional primary endpoint that has been selected for clinical trials is the forced vital capacity (FVC) [38] . Its mean value in our study population was pretty high (108.52 ± 17.40) and only 5% of them had values <80%. However, when considering the restrictive pattern treshold of FEV 1 /FVC >80 then we noticed that 38% of our patients had lung restriction. In addition, the disease may predominantly aff ect the airways in some of the patient population and [39, 40] . So, reliability of the Serbian verssion of the LCQ proved to be excellent. Th e subscale "physical" was the one with the weakest performance regarding internal consistency and it is in accordance with the results of Schupp and coauthors who validated the German version of the LCQ among 200 sarcoidosis patients [8] . Cronbach's alpha coeffi cients were similar with those in our study. Moreover, in other studies that validated the LCQ [6, 10, 12, 14] , Cronbach's alpha values were also the lowest for Physical domain (Table 4). On the other hand, Cronbach's alpha values were highest for Psychological domain of the LCQ.
Concurent validity proved to be strong when LCQ scores were compared to the severity of the most frequent symptoms of sarcoidosis patients -dyspnea and fatigue, as well as to their general healt as assessd by the 15D questionnaire. In other publish studies [12, 13, 16, 19, 41] correlations between LCQ scores and diff erent PROs (mainly genetic QoL instruments) were mostly moderate as it was also the case with the original LCQ validation [6] .
Concurent validity of the Polish LCQ [12] was tested in chronic cough patients population by comparing it with frequently used PROs -the respiratory-specifi c St. George's Respiratory Questionnaire (SGRQ) [42, 43] , generic QoL instruement Euro-Quality of Life Questionnaire (EQ-5D) [44] together with its related Visual Analogue Scale (EQ5D-VAS), and Hospital Anxiety and Depression Scale (HADS) [45] . All correlations were signifi cant, except for those with the HADS. Th e strongest correlations of total LCQ scores were noticed with the generic EQ-5D questionnaire (Spearman's coeffi cient was -0.49, p = 0.002), that is in accordance with the result of our study when the total LCQ scores were compared with scores of generic 15D insturment (Pearson's coeffi cient 0.59, p<0.001).
Similar degree of correlation was seen during the validation of Korean LCQ [14] among patients wiht chronic cough, where it was compared with the most commonly used generic health status questionnarioe SF-36 (Spearman's correlation coeffi cient for total scores was 0.55, P<0.0001) [46] .
Berkhof et al [21] validated the Dutch version of the LCQ in COPD patients and assessed concurent validity comparing it with the SGRQ and SF-36 scores. Th eir results were in accordance with other autohors, with expected stronger correlations noticed with SGRQ than with SF-36.
In the other study of validation of the Durch LCQ in chronic cough patients Huisman and coauthors [10] compared its scores with SF-36 and HADS. Correlations with SF-36 scores were statistically signifi cant, and it was also the case for HADS that was diff erent from results in the study of Dąbrowska and coworkers [12] .
LCQ scores in our study significantly correlated with all pulmonary function parameters. However, correlations of LCQ scores and pulmonary function tests in diff erent patients' populations were not frequently performed. Judson et al found that cough was not statistically signifi cantly diff erent in terms of spirometric measures (FEV 1 %, FVC% and FEV 1 /FVC) [7] .
Spanish study of LCQ validation in children with cystic fi brosis [22] (CFQ-R) [47] and spirometry parameters FEV 1 and FVC. All these correlations were statistically signifi cant. Th e degree of correlation with spirometry parameters was higher than in our study for patients with sarcoidosis.
CONCLUSION
We conclude that the Serbian version of LCQ is a valid instrument for monitoring the infl uence of chronic cough on QoL in sarcoidosis patients. In comparison to other versions translated to other languages, its psychometric charactersistics are similar and we can recommend its use in clinical practice and research in sarcoidosis patients.
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